Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18389125 | 0.82 | TSHR (0.35) | P2RX7TSHRHSD17B10POLBGAA | |
| SCHEMBL16231394 | 0.74 | SRD5A1 (0.38) | P2RX7TSHRNPSR1KMT2AKDM4E | |
| SCHEMBL2046360 | 0.74 | SRD5A1 (0.38) | P2RX7TSHRNPSR1KMT2AKDM4E | |
| SCHEMBL29348244 | 0.73 | CA1 (0.32) | — | |
| SCHEMBL24731109 | 0.71 | TSHR (0.38) | P2RX7TSHRHSD17B10POLBGAA | |
| SCHEMBL22541564 | 0.71 | TSHR (0.38) | P2RX7TSHRHSD17B10POLBGAA | |
| SCHEMBL4338609 | 0.71 | TSHR (0.38) | P2RX7TSHRHSD17B10POLBGAA | |
| SCHEMBL17586325 | 0.71 | — | — | |
| SCHEMBL16230668 | 0.71 | — | — | |
| SCHEMBL2706865 | 0.69 | TSHR (0.37) | P2RX7TSHRHSD17B10POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | GILEAD SCIENCES, INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | BCL2, BAK1, BRD4 | P2RX7 4723/4885TSHR 4060/4885HSD17B10 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.